ClearPoint Neuro (NASDAQ:CLPT) Upgraded by Wall Street Zen to "Hold" Rating

Key Points

• ClearPoint Neuro (NASDAQ:CLPT) has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, reflecting a shift in analyst sentiment.
• Stifel Nicolaus raised the price target for ClearPoint Neuro's shares from $8.00 to $9.00, indicating confidence in the company's growth potential.
• Despite this positive outlook, ClearPoint Neuro's stock has experienced a recent decline of 5.4%, with current trading at $10.49.

Wall Street Zen upgraded shares of ClearPoint Neuro (NASDAQ:CLPT - Free Report) from a sell rating to a hold rating in a research note published on Saturday morning.

Separately, Stifel Nicolaus upped their target price on shares of ClearPoint Neuro from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, ClearPoint Neuro has an average rating of "Buy" and an average price target of $19.67.

ClearPoint Neuro Stock Up 6.5%

Shares of NASDAQ:CLPT traded up $0.69 during midday trading on Friday, reaching $11.35. The company's stock had a trading volume of 244,887 shares, compared to its average volume of 251,736. The company has a quick ratio of 6.45, a current ratio of 7.30 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $322.68 million, a P/E ratio of -14.01 and a beta of 0.89. The firm has a 50 day moving average of $10.86 and a 200-day moving average of $11.97. ClearPoint Neuro has a 12-month low of $9.76 and a 12-month high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $9.22 million for the quarter, compared to the consensus estimate of $9.20 million. ClearPoint Neuro had a negative net margin of 66.15% and a negative return on equity of 94.44%. ClearPoint Neuro has set its FY 2025 guidance at EPS. On average, research analysts anticipate that ClearPoint Neuro will post -0.66 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Osaic Holdings Inc. increased its position in shares of ClearPoint Neuro by 119.8% during the second quarter. Osaic Holdings Inc. now owns 7,705 shares of the company's stock worth $92,000 after purchasing an additional 4,200 shares in the last quarter. Man Group plc raised its position in ClearPoint Neuro by 17.4% in the 2nd quarter. Man Group plc now owns 71,884 shares of the company's stock valued at $858,000 after purchasing an additional 10,674 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in ClearPoint Neuro in the 2nd quarter valued at about $219,000. BNP Paribas Financial Markets raised its position in shares of ClearPoint Neuro by 2,435.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company's stock worth $27,000 after acquiring an additional 2,143 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of ClearPoint Neuro by 315.0% during the 2nd quarter. Bank of America Corp DE now owns 113,698 shares of the company's stock worth $1,358,000 after acquiring an additional 86,304 shares in the last quarter. 30.08% of the stock is owned by institutional investors and hedge funds.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.